Viral Vectors in Cancer Immunotherapy

Erscheinungsjahr 2023
ISBN: 978-0-443-19249-4
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 151 mm x 229 mm, Gewicht: 450 g

Viral Vectors in Cancer Immunotherapy, Volume 379 in the International Review of Cell and Molecular Biology presents the latest on cancer immunotherapy and how it has transformed cancer treatment through advances in immune checkpoint inhibitors and adoptive cell therapy. Chapters in this new release include Past, present and future of viral vectors in cancer immunotherapy, Alphaviruses in cancer immunotherapy, Adenoviral-based cancer gene therapy, Armored modified vaccinia Ankara in cancer immunotherapy, Strategies of Semliki Forest virus in immuno-oncology, Maraba virus in cancer immunotherapy, Oncolytic viruses in hematological malignancies, Oncolytic virus for cancer therapies: Overview and future directions, and more.

The use of genetically modified viruses allows the expression of pro-inflammatory molecules, while the immune system receives danger signals from the viruses themselves. In some cases, the virus can also induce tumor cell death. This book will review advances in virus-based cancer immunotherapy in both solid tumors and hematologic malignancies.

Autoren/Hrsg.

Weitere Mitwirkende

Berraondo, Pedro

Fachgebiete

• Naturwissenschaften Biowissenschaften Molekularbiologie
• Naturwissenschaften Biowissenschaften Zellbiologie
• Naturwissenschaften Biowissenschaften Entwicklungsbiologie

Inhaltsverzeichnis

1. Viral Vectors Engineered for Gene Therapy

Kenneth Lundstrom

2. Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity

Noelia Silva-Pilipich, Ángela Covo-Vergara, Lucía Vanrell, and Cristian Smerdou

3. Armored modified vaccinia Ankara in cancer immunotherapy

Cigdem Atay, José Medina-Echeverz, Hubertus Hochrein, Mark Suter, and Maria Hinterberger

4. Alphaviruses in Cancer Immunotherapy

Kenneth Lundstrom

5. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success

Irati Hervás-Corpión and Marta M. Alonso

6. Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapies

Mário Sousa-Pimenta, Ângelo Martins, and Vera Machado

7. Oncolytic virotherapy in lung cancer

Estanislao Nistal-Villan, Sergio Rius-Rocabert, and Francisco Llinares-Pinel

8. Rational selection of an ideal oncolytic virus to address current limitations in clinical translation

Rupsa Basu and Chad M. Moles

Über Autor(innen)

Berraondo, Pedro
Pedro Berraondo graduated in Pharmacy at the University of Navarra in 1999. In 2004 he obtained the Ph.D. at the same university. Next, he worked at the Pasteur Institute in Paris (France) under the supervision of Dr. Claude Leclerc, where he developed novel strategies in tumor immunotherapy within the European THERAVAC project. In February 2007, he joined the Immunology and Immunotherapy Program at the Cima Universidad de Navarra, where he leads the Cytokine-based Immunotherapy laboratory. He is co-inventor of ten patents and he is co-author of more than 140 publications, including publications in Nature, Nature Medicine, Nature Reviews Drug Discovery, Immunity, Cancer Discovery, and Cancer Cell. He was certified as a full professor in 2021 by AQU. He is co-director of the degree of expert in immunooncology at the Faculty of Medicine of the University of Navarra, and is in charge of the undergraduate course of macromolecular structure at the Faculty of Sciences of the University of Navarra. He is also the coordinator of the immuno-oncology work module at CIBERONC.